Table 2.

Analysis of risk factors for mortality (60 days) in patients with PCNSL

Predictive variables	Univariate analysis			Multivariate analysisa
	HR (95% CI)	P value		HR (95% CI)	P value
Age ≥ 80	3.72 (1.14-12.10)	0.029		3.34 (1.01-11.04)	0.048
Sex (male)	1.30 (0.43-3.98)	0.642
Site
Frontal lobe	0.94 (0.31-2.88)	0.914
Parietal lobe	0.78 (0.22-2.84)	0.709
Temporal lobe	0.74 (0.23-2.40)	0.614
Occipital lobe	0.93 (0.21-4.20)	0.926
Basal ganglia	4.26 (1.31-13.85)	0.016		4.85 (1.47-15.95)	0.009
Brain stem	1.36 (0.30-6.14)	0.688
Cerebellum	2.05 (0.57-7.47)	0.274
Meninges	*	0.995
Cranial nerves	*	0.993
Max diameter ≥ 3.4	2.18 (0.67-7.08)	0.195
Number of lesions ≥ 5	2.58 (0.71-9.37)	0.150
Deep brain lesions	2.70 (0.60-12.20)	0.196
Midline shift	1.62 (0.54-4.82)	0.385
CSF involvement	*	0.998
Intraocular involvement	*	0.996
ECOG ≥ 2	5.48 (1.21-24.70)	0.027
Laboratory data
CSF protein ≥ 66.9 mg/dl	*	0.995
WBC ≥ 10,000/ul	1.32 (0.44-3.94)	0.615
Hemoglobin < 8.5 g/dl	*	0.994
Platelets ≥ 100,000/ul	*	0.993
ANC ≥ 7,278/ul	1.12 (0.38-3.35)	0.833
Albumin < 3 g/dl	1.85 (0.40-8.59)	0.430
Lactate dehydrogenase ≥ 250 U/L	1.57 (0.48-5.16)	0.454
Serum β2-microglobulin ≥ 1,613 mg/l	1.83 (0.17-20.16)	0.622
Chemotherapyb
MTX	0.20 (0.06-0.70)	0.012		0.19 (0.05-0.67)	0.010
Rituximab	0.19 (0.04-0.91)	0.037
Radiotherapy	1.65 (0.35-7.70)	0.524

HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group performance. ^aAll factors with p < 0.1 in the univariate analysis were selected for stepwise-selection Cox proportional hazards model. ^bTreatment was analyzed as a time-dependent covariate in the Cox regression model.